SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization, 2015 Apr 16, Pharmacogenomics. Li JH1, Suchindran S, Shah SH, Kraus WE, Ginsburg GS, Voora D.
- 1Duke Center for Applied Genomics & Precision Medicine, Duke University, 101 Science Drive, Durham, NC 27705, USA.
SLCO1B1 variants are associated with intermediate outcomes that may increase risk of death/myocardial infarction (MI) in statin-treatedpatients.
PATIENTS & METHODS:
In high-risk Caucasians undergoing cardiac catheterization, we tested the association between rs4149056/625T>C and rs2306283/492A>G with low-density lipoprotein cholesterol (LDL-c) over 3 years (n = 1402) and death/MI over 6 years (n = 2994), accounting for statin use or type during follow-up.
Carriers of the rs4149056 C allele had 6.2 ± 1.7 mg/dl higher LDL-c per C allele (p < 0.001) but were not at higher risk for death/MI (p = 0.9). We found no associations between rs2306283 and LDL-c or death/MI (p > 0.6).
Functional SLCO1B1 variants are not associated with death/MI in patients commonly treated with statins, despite higher LDL-c in carriers of the rs4149056 C allele. Original submitted 3 November 2014; Revision submitted 5 January 2015.